Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

BASKING RIDGE, N.J., Nov. 16, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, Ph.D., Duke University Medical Center, presented an abstract at the AHA Scientific Sessions meeting on November 16, 2010 at 10:45 a.m. CST in Chicago, IL.

The abstract, entitled "RB006, a Direct Factor IX Inhibitor Results in Consistent and Near Complete Inhibition of Factor IX in Patients with Acute Coronary Syndromes: A RADAR Pharmacokinetic and Pharmacodynamic Substudy," evaluated the appropriateness of the selected dose of pegnivacogin (a.k.a. RB006) for use in patients with Acute Coronary Syndromes.  RB006 is part of the REG1 anticoagulation system.

Regado's ongoing Phase 2b clinical trial titled: "Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome," (a.k.a. RADAR) is a partially blinded study currently enrolling 800 patients in more than 90 centers worldwide.  Patients were randomly allocated [4:1] to receive open-label RB006 or unfractionated heparin prior to catheterization and underwent various levels of double blind reversal at the end of the procedure.  This substudy, conducted in the open label portion of RADAR, included thirty patients, 20 of whom had not received recent unfractionated heparin.  It assessed PK/PD measurements just prior to and 10 minutes after dosing with RB006.  PK/PD assessments were also made, both prior to and after cardiac catheterization and before blinded dosing of anivamersen (a.k.a. RB007), RB006's complementary active control agent.  The objective was to evaluate the appropriateness of the selected RB006 dose.  
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
(Date:7/25/2014)... Recently, the largest herpes dating website ... that there had been a large increase in the number ... Living with a sexually transmitted disease can be difficult, but ... from all around the world who manage to go on ... many STDs including HSV, HPV, HIV, chlamydia, thrush, syphilis, hepatitis, ...
(Date:7/25/2014)... July 25, 2014 At World T.E.A.M. ... July 19, 17 participating developmentally-disabled teens and young adults ... if off-road bicycling, canoeing and hiking can be challenging. ... at the scenic Chesapeake and Ohio Canal National ... athletes both disabled and able-bodied. Under slightly overcast skies ...
(Date:7/24/2014)... U.S. Preventive Services Task Force recently recommended computerized ... risk for cancer, but a potential problem with ... results on the screening test, only to be ... expressed concern that this high false-positive rate will ... study of National Lung Screening Trial participant responses ...
(Date:7/24/2014)... July 24, 2014 Ticket Down is ... Tickets in Denver at the Sports Authority Field on July ... World Football Challenge) has brought some of the best club teams ... the World Cup still being raved about weeks after its completion, ... to see some of the biggest stars in the world compete. ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3
... finding, appearing online in the journal Circulation, is the first ... work was done in mice, researchers say it is likely ... progresses in humans. , Dr. Brian Annex, professor of ... study stemmed directly from his clinical experience. Over and ...
... Center will conduct a series of public town hall meetings to ... proposed large cohort study on the role of genes and environment ... effort to inform the National Institutes of Health and other federal ... study might go forward. , One way to study a ...
... SANTA CLARA, Calif., Feb. 22 Finesse Solutions, ... life sciences process,applications, announced the appointment of John ... Mr. O,Connell is a,seasoned executive with over 25 ... most recently at OSIsoft where he successfully initiated,partner ...
... /PRNewswire-FirstCall/ - In light of Neurochem,Inc.,s (NASDAQ: ... Company,announces the departure, effective February 21, 2008, of ... Orfanos, MBB. Ch, MBA, Executive Vice,President, Strategic Planning ... President, Business Development. The possibility of their,acting as ...
... Medical,Center has opened a new Sleep Diagnostic Center ... with sleep disorders. The new center provides,two specially ... leg syndrome, narcolepsy, snoring, sleepwalking, and,other sleep difficulties., ... suffer from sleep disorders,according to the American Academy ...
... DVD images create peaceful visual environment, ease anxiety of ... care facilities, WASHINGTON TOWNSHIP, N.J., Feb. 21 ... tension and anxiety too,often are the rule rather the ... relax ..., A new line of scenic, relaxation ...
Cached Medicine News:Health News:Genetic mutation found in peripheral artery disease 2Health News:Genetic town halls to be held in 5 US cities 2Health News:Neurochem announces departure of two members of management team 2Health News:New Sleep Diagnostic Center Opens at Methodist Mansfield 2Health News:New Scenic Relaxation Videos Help Reduce Stress, Promote Sense of Calm and Tranquility 2
... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...
... Thyroid Autoimmunity Test is an enzyme immunoassay ... autoantibodies against human thyroglobulin and human thyroid ... blood and is used as an aid ... thyroid gland disorders are characterized by detection ...
... is dot-blot assay system combining microwell EIA ... purified antigen set at a clinically meaningful ... is detected using the same reagent system ... combines antigens detected in Auto 4 detecting ...
... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...
Medicine Products: